

Webinář 14.dubna 2020

AGA STATEMENT

1. COVID-19 is the disease caused by the SARS-CoV-2 virus, but patients with IBD do not appear to be at a higher risk for infection with SARS-CoV-2 or development of COVID-19.
2. Patients with IBD who do not have infection with SARS-CoV-2 should NOT discontinue their IBD therapies and should continue infusion schedules at appropriate infusion centers.

AGA STATEMENT

3. Patients with IBD who have known SARS-CoV-2 but have not developed COVID-19 should hold thiopurines, methotrexate, and tofacitinib. Dosing of biological therapies should be delayed for 2 weeks monitoring for symptoms of COVID-19.
4. Patients with IBD who develop COVID-19 should hold thiopurines, methotrexate, tofacitinib, and biological therapies during the viral illness. These may be restarted after complete symptom resolution or, if available, when follow-up viral testing is negative or serologic tests demonstrate the convalescent stage of illness.

AGA STATEMENT

5. The severity of the COVID-19 and the severity of the IBD should result in careful risk-benefit assessments regarding treatments for COVID-19 and escalating treatments for IBD.
6. Please submit cases of IBD and confirmed COVID-19 to the SECURE-IBD registry at COVIDIBD.org.

Š.K. nar. 1969

- CN od r. 2002, perianální postižení, perianální a ano-vaginální píštěle
- 2018 drenáž a ano-plastika zhojena
- Od r.2017 adalimumab 40 mg s.c. a 2 týdny

- 14.1.2020 ADA TL 10.1mg/l; FC 41ug/l
- 23.3.2020 poslední aplikace adalimumabu s.c.
- 26.3.2020 SARS-CoV-2 RNA pozitivní
- Subjektivně CIVID-19 – asymptomatická

L.N. nar. 1983

- Dne 25.3. do 30.3. nachlazení, kašel, zvýšené teploty
 - Pod pravým okem pásový opar
 - 2.4. pozitivita SARS-CoV-2 RNA
 - T.č. bez obtíží
-
- Terapie byla odložena (měla být 3.4.2020) do negativity nového PCR

K.K. žena; 1976

- UC 2012 extenzivní tvar
- Terapie CS/AZA
- 2013 Infliximab
- 2015 Adalimumab
- 2016 Klinická studie Hickory – Etrolizumab ($\alpha4\beta7/\alpha E\beta7$) anti-integrin
- 2018 Cottonwood remise nemoci (Etrolizumab 107 mg s.c 1 x měsíčně) ; intermitentně Cortiment 1x ob den
- 3.4.2019 totální koloskopie Mayo 0

K.K. nar. 1976


- Poslední aplikace studijní látky 3.3.2020
- Od poloviny března 2020 intermitentně krev ve stolici, tenesmy
- Od počátku dubna bolesti v podbřišku, zvýšené teploty únava, tenesmy cca 8-10 x denně
- Laboratoř 8.4.2020. CRP 195mg/l, leu 6.4; Hb 100g/l, hcz 31.7; trombo 399; lymfo 1.3;
- COVID-19 pozitivní PCR –RNA ze stěru
- Odmítla hospitalizaci na infekčním odd. v ČB
- Váha -3 kg (61kg)

L.N. nar. 1983

- CN, v r. 2005 subtotální kolektomie a terminální ileostomie;
- Přetrvávající zánět v ponechaném pahýlu rekta a na distálním ileu cca 50cm nad stomií
- Od r. 2015 biologická léčba (adalimumab/infliximab)
- Od srpna 2019 ustekinumab
- 3.2.2020 UST TL 1.9mg/l
- Poslední aplikace 21.2020

K.K. 1976

- Léčena: Cortiment 9 mg 1x denně, Doxybene 100 mg 1x denně, lokálně : Budenofalk rektální pěna ráno + Asacol 4g klyzma večer
- Subj. trochu zlepšena, menší počet tenezmů (hlavně v noci), přetrvávají teploty, noční pocení poslední dva dny má kašel
- Dnes CT hrudníku v CB



Cases reported by country*

country	N
United States	155
Spain	81
France	49
Italy	38
United Kingdom	24
Belgium	19
Netherlands	17
Switzerland	16
Israel	11
Canada	9
Germany	9
Austria	7
Portugal	7
Brazil	5
Czech Republic	4
Missing	4
Australia	3

Cases reported by country*

country	N
Czech Republic	4
Missing	4
Australia	3
Iran, Islamic Republic of	3
Ireland	3
Turkey	3
Norway	2
Qatar	2
Bahrain	1
Bulgaria	1
China	1
Croatia	1
Finland	1
Greece	1
Hungary	1
India	1
Japan	1
Malaysia	1

Cases reported by country*

country	N
New Zealand	1
United Arab Emirates	1

Showing 1 to 34 of 34 entries

* Countries not included in this table have not reported any cases to SECURE-IBD

Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
Overall	483	331 69%	151 31%	23 5%	20 4%	16 3%	36 7%
Age							
0-9 years	2	2 100%	0 0%	0 0%	0 0%	0 0%	0 0%
10-19 years	22	19 86%	3 14%	0 0%	0 0%	0 0%	0 0%
20-29 years	106	84 79%	22 21%	2 2%	1 1%	0 0%	2 2%
30-39 years	96	76 79%	19 20%	3 3%	1 1%	1 1%	3 3%
40-49 years	86	59 69%	27 31%	4 5%	3 3%	2 2%	5 6%
50-59 years	71	44 62%	27 38%	3 4%	5 7%	2 3%	6 8%
60-69 years	53	30 57%	23 43%	10 19%	9 17%	3 6%	11 21%
70-79 years	24	7 29%	17 71%	1 4%	1 4%	2 8%	3 13%
>=80 years	21	8 38%	13 62%	0 0%	0 0%	6 29%	6 29%

Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
Sex							
Male	255	168 66%	87 34%	12 5%	9 4%	11 4%	21 8%
Female	223	159 71%	63 28%	11 5%	11 5%	5 2%	15 7%



Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
Disease type							
Crohn's disease	285	205 72%	79 28%	11 4%	8 3%	5 2%	15 5%
Ulcerative Colitis/unspecified	195	124 64%	71 36%	12 6%	12 6%	11 6%	21 11%
IBD Disease Activity							
Remission	285	212 74%	72 25%	11 4%	13 5%	8 3%	18 6%
Mild	95	67 71%	28 29%	2 2%	1 1%	4 4%	5 5%
Moderate/Severe	89	44 49%	45 51%	9 10%	5 6%	3 3%	12 13%
Unknown	14	8 57%	6 43%	1 7%	1 7%	1 7%	1 7%

Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
Smoking							
Current smoker	22	11 (50%)	11 (50%)	0 (0%)	0 (0%)	1 (5%)	1 (5%)
Non-smoker	461	320 (69%)	140 (30%)	23 (5%)	20 (4%)	15 (3%)	35 (8%)
Comorbidities							
0	322	248 (77%)	74 (23%)	10 (3%)	7 (2%)	4 (1%)	12 (4%)
1	100	66 (66%)	33 (33%)	4 (4%)	4 (4%)	4 (4%)	8 (8%)
2	34	10 (29%)	24 (71%)	4 (12%)	5 (15%)	3 (9%)	7 (21%)
3+	27	7 (26%)	20 (74%)	5 (19%)	4 (15%)	5 (19%)	9 (33%)

Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
IBD medication*							
Sulfasalazine/mesalamine	109	55 50%	54 50%	12 11%	12 11%	9 8%	20 18%
Budesonide	16	9 56%	7 44%	3 19%	3 19%	1 6%	3 19%
Oral/parenteral steroids	34	10 29%	24 71%	6 18%	5 15%	4 12%	9 26%
6MP/azathioprine monotherapy	47	26 55%	21 45%	3 6%	3 6%	1 2%	3 6%
Methotrexate monotherapy	4	1 25%	3 75%	0 0%	0 0%	0 0%	0 0%
Anti-TNF without 6MP/AZA/MTX	163	138 85%	24 15%	3 2%	1 1%	1 1%	4 2%
Anti-TNF + 6MP/AZA/MTX	47	27 57%	20 43%	4 9%	2 4%	2 4%	5 11%
Anti-integrin	47	33 70%	14 30%	2 4%	3 6%	0 0%	3 6%
IL 12/23 inhibitor	43	41 95%	2 5%	1 2%	0 0%	0 0%	1 2%
JAK inhibitor	8	7 88%	1 13%	1 13%	1 13%	1 13%	1 13%
Other IBD medication	21	13 62%	8 38%	0 0%	0 0%	0 0%	0 0%

*Medication categories are not mutually exclusive